Chemical Property of Zucapsaicin
Chemical Property:
- Vapor Pressure:4.41E-11mmHg at 25°C
- Melting Point:70 °C
- Refractive Index:1.523
- Boiling Point:511.462 °C at 760 mmHg
- PKA:9.76±0.20(Predicted)
- Flash Point:263.123 °C
- PSA：58.56000
- Density:1.042 g/cm3
- LogP:4.18050
- Storage Temp.:2-8°C
- XLogP3:3.6
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:3
- Rotatable Bond Count:9
- Exact Mass:305.19909372
- Heavy Atom Count:22
- Complexity:341
- Purity/Quality:
-
97% *data from raw suppliers
cis-Capsaicin *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC
- Isomeric SMILES:CC(C)/C=C\CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
- Recent ClinicalTrials:Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve
-
Description
Zucapsaicin is a topical analgesic that was approved in Canada in July
2010 for use in conjunction with oral COX-2 inhibitors or NSAIDs to
relieve severe pain in adults with osteoarthritis of the knee. Zucapsaicin
is the cis-isomer of the natural product capsaicin. Capsaicin is
available without a prescription in creams, lotions, and patches for the
treatment of neuropathic and musculoskeletal pain. Zucapsaicin is available
as a 0.075% by weight cream. The advantages of zucapsaicin compared
with capsaicin are reported to be a lesser degree of local irritation
(stinging, burning, erythema) in patients and a greater degree of efficacy
in preclinical animal models of pain. The analgesic action of
zucapsaicin and capsaicin is mediated through the transient receptor
potential vanilloid type 1 (TRPV1) channel.
-
Uses
(Z)-CAPSAICIN is used as a tool in neurobiological research. Prototype vanilloid receptor agonist.
-
Clinical Use
Zucapsaicin, the cis-isomer of the natural product capsaicin, is a
topical analgesic that was initially developed by Winston Pharmaceuticals
and approved in Canada in July 2010 for the treatment of
severe pain in adults with osteoarthritis of the knee. The advantages
of zucapsaicin compared with naturally-occurring capsaicin
are reported to be a lesser degree of local irritation (stinging, burning,
erythema) in patients and a greater degree of efficacy in preclinical
animal models of pain. The analgesic action of both
zucapsaicin and capsaicin is mediated through the transient receptor
potential vanilloid type 1 (TRPV1) channel, a ligand-gated ion
channel expressed in the spinal cord, brain, and localized on neurons
in sensory projections to the skin, muscles, joints, and
gut.
